- Home
- CTO vs PLRX Comparison
CTO vs PLRX Comparison
Compare CTO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | PLRX |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 74.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CTO | PLRX |
|---|---|---|
| Price | $20.18 | $1.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $22.50 | $2.67 |
| AVG Volume (30 Days) | 234.1K | ★ 469.5K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $1.09 |
| 52 Week High | $20.67 | $1.95 |
Technical Indicators
Market Signals| Indicator | CTO | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.23 | 37.09 |
| Support Level | $19.22 | $1.16 |
| Resistance Level | $20.67 | $1.37 |
| Average True Range (ATR) | 0.38 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 62.31 | 2.43 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.